JPMorgan Chase & Co. Cuts Omnicell (NASDAQ:OMCL) Price Target to $36.00

Omnicell (NASDAQ:OMCL) had its price target cut by JPMorgan Chase & Co. from $44.00 to $36.00 in a research note issued to investors on Thursday morning,Benzinga reports. They currently have a neutral rating on the stock.

Several other equities research analysts have also commented on OMCL. Bank of America decreased their target price on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. Benchmark reiterated a “buy” rating and issued a $62.00 price objective on shares of Omnicell in a research report on Tuesday, February 4th. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a research report on Thursday, March 6th. Finally, Wells Fargo & Company decreased their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research report on Monday, January 13th. Four research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to data from MarketBeat.com, Omnicell currently has a consensus rating of “Hold” and an average price target of $51.00.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $33.94 on Thursday. The firm has a market capitalization of $1.59 billion, a P/E ratio of 125.71, a PEG ratio of 7.53 and a beta of 0.85. Omnicell has a one year low of $25.12 and a one year high of $55.75. The company’s fifty day moving average is $39.77 and its two-hundred day moving average is $42.90. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 6th. The company reported $0.45 EPS for the quarter, missing the consensus estimate of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Analysts forecast that Omnicell will post 1.09 EPS for the current fiscal year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Smartleaf Asset Management LLC lifted its holdings in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after purchasing an additional 273 shares in the last quarter. Johnson Financial Group Inc. purchased a new position in Omnicell in the 4th quarter valued at about $37,000. Van ECK Associates Corp lifted its holdings in Omnicell by 47.0% in the 4th quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after purchasing an additional 315 shares in the last quarter. Headlands Technologies LLC acquired a new position in shares of Omnicell during the 4th quarter valued at about $53,000. Finally, First Horizon Advisors Inc. increased its stake in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock valued at $59,000 after acquiring an additional 355 shares during the last quarter. 97.70% of the stock is currently owned by hedge funds and other institutional investors.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.